

1 **Seroprevalence and Dynamics of anti-SARS-CoV-2 antibody among healthcare workers**
2 **following ChAdOx1 nCoV-19 vaccination**
3

4
5 **Soma Sarkar^{1*}, Shantanab Das^{1,3}, Kabita Choudhury¹, Saibal Mukherjee², Raghunath**
6 **Chatterjee^{3*}**

7
8 ¹Department of Microbiology, NRS Medical College & Hospital, 138, A J C Bose Road, West Bengal, Kolkata,
9 India 700014

10 ²NRS Medical College & Hospital, 138, A J C Bose Road, West Bengal, Kolkata, India 700014

11 ³Human Genetics Unit, Indian Statistical Institute, 203 B. T. Road, Kolkata, West Bengal, India 700108
12

13
14 *Authors for correspondence:

15 E-mail:- drdssarkar@gmail.com; Tel: +91 99030 79171

16 E-mail:- rchatterjee@isical.ac.in; Tel:- +91 33 2575 3243; Fax:- +91 33 2577 3049
17

18 **Running title:** SARS-CoV-2 infection, vaccination and IgG dynamics
19

20
21 **Keywords:** Immunoglobulin G; Seroprevalence; SARS-CoV-2 vaccine; COVISHILED; Neutralizing antibody;
22 Anti-SARS-CoV-2 IgG Antibody stability
23
24

1 **Abstract**

2 **Background**

3 The serological evaluations of IgG, IgM, and IgA to the SARS-CoV-2 proteins are widely used for the
4 epidemiological assessment of COVID-19. The Health Care Workers (HCWs) are presumably exposed to a
5 higher risk of acquiring the disease owing to their regular contact with the patients.

6 **Methods**

7 COVID-19 prevalence was investigated by classifying 313 HCWs into four groups based on their degree of
8 exposure and estimating the IgG and total antibody. The serological assessment of the anti-SARS-CoV-2
9 antibody was conducted 21 days post-vaccination of first or both doses of the ChAdOx1 nCoV-19 vaccine
10 among 174 HCWs. The vaccinated HCWs were followed up for 3 months for SARS-CoV-2 infection.

11 **Findings**

12 The levels of anti-SARS-CoV-2 IgG were comparable among different groups, but the seroprevalence gradually
13 decreased from the most exposed to the less exposed group. The neutralizing antibody was positively correlated
14 with IgG as well as total antibody. IgG was marginally decreased after 2 months followed by a significant drop
15 after 4-6 months post-infection. However, 80% of the HCWs developed a detectable amount of IgG after the
16 first dose of vaccination, the median titer of which was comparable to the seropositive HCWs after natural
17 infection. Almost 100% of the HCWs developed antibodies after the second dose of vaccine with boosting effect
18 among the seropositive HCWs. Although ~11.5% of the vaccinated HCWs were infected with the SARS-CoV-
19 2, ~94% of them showed mild symptoms and recovered in home isolation without any O₂ support.

20 **Interpretations**

21 The varying level of seroprevalence among the four groups suggested stratified spread of the disease. One dose
22 of SARS-CoV-2 vaccination was found to be effective in terms of the antibody titer, while the second dose was
23 required to cover the larger population. The effectiveness of the ChAdOx1 nCoV-19 vaccine was noticeable due
24 to the low rate of post-vaccination infection with moderate or severe symptoms.

25

1 Introduction

2 Coronavirus disease 2019 (COVID-19) started as a regional epidemic in December 2019 in Wuhan, China, but
3 its rapid expansion made it a global pandemic affecting almost all the countries and significant mortality^{1,2}.
4 While every affected country has taken containment and mitigation measures, the spread of COVID-19 is still
5 prominent³. The spectrum of clinical syndromes caused by SARS-CoV-2 ranges from asymptomatic cases to
6 mild flu-like symptoms to severe pneumonia, acute respiratory distress syndrome (ARDS) and death. Many
7 experts believe that unnoticed, asymptomatic cases of coronavirus infection could be the hidden source of
8 contagion⁴⁻⁷. The Health care workers (HCW) are the frontline workforce for clinical care and are presumably
9 exposed to a higher risk of acquiring the disease than the general population. If infected, they not only pose a
10 risk to the vulnerable patients and the fellow HCW⁸⁻¹⁰ but associated morbidity and mental stress also cause
11 disruption of patient care¹¹.

12 After primary infection, IgG antibody production can be maintained for a long time in any viral infection¹². The
13 cell entry of SARS-CoV-2 is facilitated by interaction of the spike (S) glycoprotein through its receptor-binding
14 domain (RBD) to the human ACE2 (hACE2) receptor and IgG antibody develops between 6-15 days following
15 the disease-onset¹³. The seroprevalence studies give us an indirect estimate of the proportion of HCWs who
16 have experienced recent or past infection with COVID-19. Monitoring the prevalence of infection among HCW
17 (regardless of history of symptoms) is useful for assessing the extent of exposure among the hospital personnel
18 and identifying the high-risk groups. Considering the urgent need of vaccine across the globe, 120 vaccine
19 candidates were reported within the first 5 months of 2020¹⁴. Many countries including India have initiated the
20 vaccination drive¹⁵. Apart from clinical trial data more insights on antibody production are also needed for
21 evaluation of the results of vaccination considering development of protective as well as therapeutic antibodies.
22 Amidst the slow vaccination process in India, the number of cases significantly increased during the second
23 wave¹⁶.

24 Although there is evidence on the immunological responses against SARS-CoV-2, but the time to
25 seroconversion and the antibody levels elicited in relation to the patient profile are not fully characterized yet.
26 Importantly, the correlation between seropositivity or antibody levels and protection against re-infection, as well
27 as the duration of protective immunity, remains to be elucidated.

28 The present study highlights several key aspects of antibody generation among HCWs in a tertiary care hospital
29 of Kolkata. We determined the overall infection prevalence (past and current) to SARS-CoV-2, the prevalence
30 of asymptomatic infections, SARS-CoV-2 antibody kinetics and longevity as well as the development of
31 protective antibody in HCWs following infection. Additionally, we also investigated the level of neutralizing
32 antibody and its relationship with the IgG and total antibody among seroreactive individuals. The levels of
33 antibody production after first and second doses of vaccination were also investigated among the HCWs. The
34 rate of infection among the vaccinated HCWs within 3 months post-vaccination and the degree of severity and
35 hospitalization in case of infection were also evaluated.

36

37 Materials and Methods

38 Study setting

39 This cross-sectional study among the health care workers (HCWs) was executed at a tertiary care hospital,
40 Kolkata after obtaining approval from the Institutional Ethics Committee, Nilratan Sircar Medical College &
41 Hospital. Among the 3,997 HCWs in the tertiary care center, 313 HCWs (11 Administrative staff, facility
42 manager and clerical staff, 66 Junior doctors, 38 Medical officer, 81 Nursing staff, 24 Paramedical staff and
43 research scientist, 93 Support staff, GDA, security, kitchen staff) were randomly selected and included in the
44 study with their informed consent for serosurvey during November 2020 to January 2021. The follow up and
45 antibody response studies following vaccination were conducted during January 2021 to June 2021.

46 The study population were chosen randomly irrespective of their working department and divided into 4 groups
47 (A, B, C and D) based on their working area, direct care to COVID-19 patient, face-to-face contact (within 1
48 meter) and duration of exposure to the COVID patients, performed any aerosol-generating procedures or direct
49 contact with the environment where the confirmed COVID-19 patient was cared like bed, linen, medical
50 equipment, bathroom etc.¹⁷. Individuals within Group A were the most exposed and Group D were the least.
51 HCWs with 5 hours of cumulative exposure per day to the covid patient directly or indirectly were included in
52 Group A. Those HCWs with 4hrs, 3hrs and 1hr cumulative exposure per day to the COVID-19 patient were
53 included in Group B, Group C and Group D, respectively. Participants with symptoms suggestive of recent
54 infection or positive RT-PCR test result within last 14 days were excluded from the study. A structured
55 questionnaire comprising demographics, prior symptoms with their duration, prior COVID-19 test results,
56 working location (in terms of working in COVID or Non-COVID unit), co-morbidities were collected prior to
57 the blood collection for SARS-CoV-2 antibody testing.

1 Serological analysis of IgG and Total Antibody

2 Serum samples were prepared from the clotted blood following centrifugation for 10 minutes at 3000g at room
3 temperature. Serological analysis of IgG and total antibody (IgG, IgM and IgA) were performed using enhanced
4 chemiluminescence technology by Vitros ECiQ (Ortho Clinical Diagnostics, New Jersey, US). In this immuno-
5 metric technique, antibodies to SARS-CoV-2, if present in the sample bind to the SARS-CoV-2 spike protein
6 coated on the wells. When horseradish peroxidase (HRP) labelled murine monoclonal anti-Human IgG
7 antibodies were added as conjugate, the conjugate interacted specifically to the antibody portion of antigen-
8 antibody complex which is measured by a luminescent reaction. After the addition of luminogenic substrate,
9 HRP bound conjugate catalyzes the oxidation of the luminal derivative, producing light. The electron transfer
10 agent (substituted Acetanilide) increases the level of light and prolongs its emission. The amount of HRP
11 conjugate bound is directly proportional to the amount of SARS-CoV-2 antibody present in the sample¹⁸.

12 Neutralizing antibody sandwich ELISA

13 To find out whether the seropositive patients were also developing the neutralizing antibody, a neutralizing
14 antibody sandwich ELISA (GenScript, USA) following manufacturer's protocol was also performed. SARS-
15 CoV-2 spike protein contains a receptor binding domain (HRP-RBD), which recognizes the human ACE2
16 receptor (hACE2) protein on the cell surface and leads to endocytosis into the host cell. This neutralization
17 assay mimics the virus neutralization process through virus-host interaction. The diluted samples, if contains
18 neutralising antibody, bound with HRP-RBD and the protein-protein interaction between HRP-RBD and
19 hACE2 is blocked by neutralising antibody (blocking ELISA)¹⁹.

20 Dynamics of IgG antibody over time

21 Among 313 HCWs, 104 were RT-PCR confirmed COVID-19 patients. To evaluate the dynamics of the
22 antibody titer, all RT-PCR confirmed COVID-19 HCWs were followed up at two months interval for six
23 months of their first antibody measurement.

24 Seroreactivity after vaccination

25 247 HCWs, who received ChAdOx1, nCoV-19 corona virus vaccine (COVISHIELD), a replication deficient
26 simian adenoviral vector that expresses full length Spike (S) protein of SARS-CoV-2²⁰, were included in the
27 study. Blood samples were collected from 130 HCWs twenty-one days after first dose and from 76 HCWs
28 twenty-one days after second dose (32 HCWs were common in both doses) of ChAdOx1, nCoV-19 vaccine for
29 anti-SARS-CoV-2 antibody testing.

30 Statistical Analyses

31 Descriptive as well as inferential analyses were performed using R Software²¹. A significance level of $p \leq 0.01$
32 was considered unless it was specifically mentioned.

33 Results

34 The mean age of the 313 HCWs was 37.83 (SD=12.31) with 54% male and 46% female. Around 51% of them
35 were involved in direct care of the COVID-19 patients with different level of exposures. Based on their
36 occupational risks and degree of exposures, HCWs were classified into four groups. The mean ages of all four
37 groups were also approximately similar. Besides their co-morbidities, COVID-19 like symptoms, working in
38 COVID unit and use of prophylactic drug was also recorded for each subject (Table 1).

39 Serological analysis of IgG and Total Antibody

40 Around 34% (106) of the HCWs were seropositive for IgG while 40% (126) of them were seropositive for total
41 antibody (IgG, IgM and IgA). The median IgG titer (signal to cut-off ratio, henceforth referred as S/Co ratio)
42 was 6.30 with median absolute deviation (MAD) was 3.27 for IgG reactive individuals. Whereas the median
43 total antibody titer was 141 S/Co ratio (MAD=101.60) among seroreactive HCWs. Seroprevalence was not
44 significantly different with respect to age or sex of the HCWs (p -value=0.4798, OR=1.18, 95% CI=0.74-1.88).
45 Although the median IgG titer were comparable for four groups (median S/Co ratio for Group A = 5.48 and
46 MAD = 3.65, Group B = 6.08 and MAD =3.49, Group C = 6.22 and MAD=2.68 and Group D = 7.89 and MAD
47 =2.86), but the seroprevalence was higher in Group A (53.8%) and gradually decreased for Group B (40.7%),
48 Group C (31.8%), and Group D (25.8%) for total anti-SARS-CoV-2 antibody (Figure 1a). Whereas for IgG,
49 Group A (38.4%) and Group B (39.5%) showed similar seroprevalence and significantly lower prevalence in
50 Group C (30.3%), and Group D (22.5%) (Figure 1A). We further investigated the total antibody titers among
51 IgG reactive and non-reactive individuals. The level of total antibody among IgG reactive HCWs were
52 significantly higher compared to the level of IgG, suggesting presence of IgM and IgA (Figure 1B). Total
53 antibody among IgG non-reactive HCWs varied from 0 to 140 S/Co ratio (Figure 1C). Around 35% HCWs, who

1 worked in the COVID-19 unit were seropositive. A similar proportion of seropositive HCWs were also observed
2 in non-COVID unit HCWs (p-value=0.9154, OR=1.08, 95% CI=0.64-1.63). Following ICMR guidelines²²,
3 HCWs were advised to consume hydroxychloroquine (HCQ) as a prophylactic medication. In our entire study
4 population only 27% have consumed HCQ as prophylaxis. The seropositivity among HCQ consumer and non-
5 consumer was not significantly different (p-value=0.3285, OR=0.776, 95% CI=0.44-1.30) (Table 2). As
6 consumption of HCQ did not significantly affect the entire population, we didn't pursue it for further analysis on
7 group wise effect of HCQ.

8 Next, we wanted to evaluate the IgG prevalence among symptomatic and asymptomatic HCWs. Around 38% of
9 the studied population developed at least one of the COVID-19 symptoms in recent past. We identified 24% of
10 the asymptomatic HCWs developed IgG, whereas 52% of the symptomatic individuals were found to be
11 seropositive for SARS-CoV-2 antibody (OR=3.49, 95% CI=2.14-5.70, p-value= 3.5×10^{-7}) (Figure 1D). We
12 further evaluated the association of seropositivity among different COVID-19 suggestive symptoms, and found
13 a significant association with all symptoms, among which fever and headache showed higher significance
14 compared to other symptoms (OR=3.397, 95% CI=2.05-5.62, p-value= 1.179×10^{-6}) (Table 2).

15 **Neutralizing antibody sandwich ELISA:**

16 To assess the extent of neutralizing activity of the seropositive HCWs, we randomly selected 46 individuals
17 from the IgG seroreactive group and determined the level of neutralizing antibody. The level of neutralizing
18 antibody was found to be positively correlated with the IgG S/Co ratio ($R^2=0.8363$, p-value<0.001) (Figure 2A)
19 suggesting that the IgG seropositive HCWs developed the protective antibody against SARS-CoV-2.

20 **Case infection ratio among HCWs:**

21 We further analysed the case detection using RT-PCR among the four groups of seropositive HCWs. Around
22 84% of RT-PCR positive HCWs showed detectable IgG, whereas 92% of the HCWs showed detectable level of
23 total antibody. We determined the case-infection ratio for each group, where case refers to the RT-PCR tested
24 COVID-19 positive cases and infection refers to the seroreactive individuals in each group. Among the total
25 samples, we found a case-infection ratio of 0.48 for IgG, suggesting that around half of the HCWs did not opt
26 for the RT-PCR test (Figure 2B). In group wise analysis, a gradual increase of case-infection ratio from Group
27 A to Group D was observed for both IgG and total antibody (Gr A= 0.27, B=0.53, C=0.60 and D=0.78).

28 **Dynamics of anti-SARS-CoV-2 IgG antibody over time**

29 To evaluate the antibody titer over time, we classified the RT-PCR confirmed COVID-19 HCWs with respect to
30 time duration of COVID-19 RT-PCR testing to the first IgG measurement. The IgG and total antibody titers
31 were found to be decreasing with times. The median value of IgG S/Co ratios were found to be 7.75
32 (MAD=2.77), 5.97 (MAD=3.21) and 1.70 (MAD=1.685) at 0-2 months, 2-4 months, and 4-6 months,
33 respectively. Both IgG and total antibody titers were found to be significantly decreasing at 4-6 months post-
34 infection (p=0.04) (Figure 3A, B). To get more insight about this trend, we classified HCWs into three groups
35 having IgG titers of 1-3, 3-6 and >6 S/Co ratio and estimated the proportion of individuals within each group.
36 Around 69% of HCWs showed IgG > 6 S/Co ratio between 0-2 months and started decreasing at 2-4 months
37 followed by a significant drop at 4-6 months post-infection (Figure 3C). To substantiate this observation, we
38 performed a follow up study with randomly selected 42 IgG seropositive individuals at 2 months interval. The
39 IgG titer at 0-2 months showed a significant decrease at 2-4 months (p=0.002) indicating the significant
40 decreasing trend of IgG over time (Figure 3D).

41 **Seroreactivity after vaccination**

42 Next, we evaluated the effect of vaccination on development of anti-SARS-CoV-2 IgG. IgG titers of 130 HCWs
43 after first dose and 76 HCWs after second dose of ChAdOx1 nCoV-19 vaccine were determined. Around 80%
44 of the HCWs, who has taken first dose have developed detectable IgG, but surprisingly remaining 20% of them
45 did not develop detectable amount of antibody against SARS-CoV-2 after 21 days from the first dose of vaccine
46 (Figure 4A). To better understand the antibody response among these non-reactive individuals, we categorized
47 the first dose post-vaccination HCWs according to previous IgG status. It was observed that the IgG titer was
48 significantly enhanced to 14.7 S/Co ratio (MAD=0.9) after first dose of vaccination compared to previously
49 seropositive (7.18 S/Co ratio (MAD=3.12)) HCWs (p<0.0001) (Figure 4B). In case of previous seronegative
50 HCWs, the median IgG was found to be 7.26 S/Co ratio (MAD=2.74) after first dose of vaccination (Figure 4C).
51 Notably, the RT-PCR confirmed COVID-19 HCWs showed a median IgG titer of 8.25 S/Co ratio (MAD=1.38)
52 within 1-2 months post infection, indicating comparable effect of the first dose of vaccination with that of the
53 natural infection by SARS-CoV-2 (Figure 4D). This observation clearly indicated that the first dose of vaccine
54 among previously seropositive individuals acted as booster to enhance the level of antibody.

55 Most of the vaccination strategy used a two-dose programme for the complete vaccination. To evaluate the
56 antibody dynamics following two doses of vaccination, we determined the IgG of 130 HCWs after first dose and

1 76 HCWs after second dose of vaccine. Twenty-one days post first dose of vaccination, we found ~20% HCWs
2 remained seronegative while ~100% of them become seropositive after 21 days post second dose of vaccination,
3 suggesting importance of second dose of vaccine (Figure 4E). We further classified the HCWs as first dose non-
4 reactive and reactive groups and determined antibody titer following 2 doses of vaccination. Interestingly, the
5 non-reactive individuals after first dose of vaccination became seropositive to anti-SARS-CoV-2 IgG after the
6 second dose ($p=0.0001$) (Figure 4E), whereas the IgG titer after second dose (median=10.7, MAD=3.8)
7 significantly enhanced compared to first dose (median=7.26, MAD=5.9) ($p<0.0001$) (Figure 4F). Longitudinal
8 data of anti-SARS-CoV-2 antibody replicated the general observation of significant enhancements after both
9 first and second doses of ChAdOx1 nCoV-19 vaccine compared to the antibody titer before vaccination (Figure
10 4G).

11 In our cohort of 313 HCWs, 247 HCWs received both doses and 19 received only first dose of the ChAdOx1
12 nCoV-19 vaccine until June 2021. Among 266 ChAdOx1 nCoV-19 vaccinated HCWs, 31 (11.5%) were
13 infected with SARS-CoV-2 within three months post vaccination. Interestingly, 94% of the infected HCWs
14 showed either mild or no symptoms and recovered in home isolation without requirement of any O₂ support.
15 Only 1 HCW needed hospitalization with severe symptoms and O₂ requirement. To evaluate whether the level
16 of antibody could serve as a possible indicator of post vaccination infection, we compared the median antibody
17 titer among the post-vaccination uninfected and infected HCWs. The median antibody S/Co ratio for the
18 infected HCWs (median=5.94, MAD=2.225) was significantly less compared to the uninfected HCWs
19 (median=10.7, MAD=3.8) ($p<0.001$) (Figure 4H), suggesting a possibility of SARS-CoV-2 infection among the
20 low antibody titer seropositive individuals. Note that other factors such as degree of precautionary measures,
21 occupational risk factors among these groups might also be a perilous factor for such infection.
22

23 Discussion

24 To understand the transmission dynamics of SARS-CoV-2 virus, seroprevalence is important to guide
25 interventions for control of COVID-19 pandemic. Beside the RT-PCR based detection, the seroprevalence acts
26 as an important measure of the potential past infection for mild and asymptomatic patients. In a tertiary care
27 hospital set up, seroprevalence guides the COVID-19 infection dynamics among the different working groups²³.
28 As HCWs are the most exposed to SARS-CoV-2 infection, determination of seroprevalence among different
29 working groups is an effective indicator to monitor and control the spread of SARS-CoV-2 infection.
30 Seroprevalence rate was found to be different among HCWs in several countries due to various factors like
31 selection bias in recruiting study participants, study period, awareness and effective implementation of infection
32 control practices, adequate use of PPE, maintenance of hand hygiene and physical distance, early identification
33 and timely isolation and quarantine as well as seroprevalence rate in the community²⁴⁻²⁸.

34 In this study, the seropositivity among HCWs in a tertiary care hospital was 34% for IgG during November
35 2020 to January 2021, which was similar to a study conducted during April 2020 among the HCWs at a tertiary
36 hospital in New York city, USA (36%)²⁹. It was observed that the seroprevalence among HCWs in this study
37 was higher to the reported seroprevalence of 26% among the HCWs in Kolkata during September 2020²⁸. The
38 third pan India serosurvey, conducted during December 2020-January 2021 also reported 25.6% seroprevalence
39 among the HCWs in India³⁰, suggesting variable seroprevalence among the HCWs across different parts of the
40 country. In contrary to our observation, the pan India serosurvey did not identify any difference in
41 seroprevalence between different HCW categories. This difference might be due to inadequate stratification of
42 risk groups among the HCWs. However, variable prevalence among HCWs across different parts of the country
43 might also impact the results of their study.

44 The overall seroprevalence data showed no significant association with age or sex, as also was observed in
45 second and third pan India serosurvey conducted in August and December 2020^{30,31}. As Group A and Group B
46 were mostly exposed to COVID-19 patients, seropositivity of these two groups was similar, whereas Group C
47 and Group D showed significantly low seropositivity compared to groups A and B. The decreasing trend of
48 seroprevalence ranging from 54% to 23% from high risk to low-risk group for both IgG and total antibody
49 vividly portrayed the association of seroprevalence with SARS-CoV-2 infection risk. The total antibody titer
50 (S/Co ratio) was significantly higher than IgG because it includes IgA, IgM along with IgG. Among the IgG
51 non-reactive individuals, 10% showed presence of detectable amount of total anti-SARS-CoV-2 antibody,
52 suggesting presence of only IgA and IgM. The pan India serosurvey also reported variable seroprevalence in
53 urban and rural areas with higher prevalence in urban slum areas than rural areas³¹.

54 Working in COVID-19 or non-COVID-19 unit was not associated with increased antibody positivity in HCWs.
55 The seroprevalence study from Spanish hospital also found no association of COVID-19 with working in
56 COVID unit suggesting that awareness and strict adherence to infection control protocols were sufficient to
57 prevent transmission to HCWs²⁵.

1 This study also evaluated the effect of HCQ as prophylaxis for COVID-19 in terms of seroprevalence among the
2 HCQ consumers and non-consumers. In a hospital based seroprevalence study in Kolkata, there was a
3 significant association of seroreactivity with adequate HCQ consumption as only 1.3% of HCQ consumers
4 became reactive²⁸. But in this study, we did not find any effect of HCQ prophylaxis on seroprevalence of
5 COVID-19.

6 We know that the cellular immune response plays an important role to clear the virus from host cell and humoral
7 immune response is responsible for preventing future infection. Although the plaque reduction neutralization
8 test (PRNT) is the gold standard for neutralization assays, it is cumbersome, time consuming and require
9 Biosafety Level 3 facilities. Therefore, we performed ELISA based neutralizing assay to substantiate the
10 preventive immunity of anti-spike IgG and found 100% of seropositive individuals developed detectable
11 neutralizing antibody. The signal cut-off values of detected IgG were directly proportional to the level of
12 neutralizing antibody.

13 We found a positive correlation of both IgG and total antibody reactivity with COVID-19 suggestive symptoms
14 developed throughout the course of the disease as 52% of all symptomatic individuals were seroreactive. So,
15 early identification of suggestive symptoms acts as a predictive indication of SARS-CoV-2 infection and based
16 on that self-isolation can be recommended to prevent the further spread. Seroprevalence study at Sweden
17 showed that almost all COVID-19 symptoms were highly associated the seroreactivity²⁶. The first
18 seroprevalence study at Belgium also found significant association of COVID-19 symptoms with
19 seroprevalence²³.

20 Detection of RNA of SARS-CoV-2 by RT-PCR or humoral responses to the virus (detectable IgG) is the
21 evidence of SARS-CoV-2 infection. Here we determined the RT-PCR positive cases among IgG positive HCWs
22 as case infection ratio for each group in our cohort. The gradual increasing trend of case infection ratio from
23 group A to group D decisively showed that most of the infections were undetected in HCWs from high-risk
24 groups whereas the low-risk group HCWs were aware of their infection and did RT-PCR test in time.

25 On the other hand, the durability of the antibody titer depends on its initial titer and the time of measurement
26 following infection or vaccination. We found that IgG titer was significantly reduced after 4 to 6 months of
27 infection and the proportion of individuals in each IgG titer level decreased over time. A brief follow-up after 2
28 months, with randomly selected 42 seropositive individuals also substantiated the decay kinetics of IgG. This
29 data was concomitant with the study by Wajnberg et al., where it was shown that the titer could last up to 5
30 months³². A CDC report on November 2020 showed similar observations where 94% of 156 seropositive
31 HCWs experienced a rapid decline in antibody titer after 60 days of initial observation³³.

32 The remarkable volume of knowledge accumulated from the scientific quest during this pandemic helped in
33 yielding actionable insights which lead to develop vaccines and therapeutic strategies against COVID-19. As of
34 now, 102 vaccine candidates are at various stages of clinical trials, and 184 vaccines are in preclinical
35 development spanning diverse vaccination platforms¹⁴. Administration of adenovirus-based vaccines
36 COVISHIELD was initiated in India for HCWs in early January, 2021¹⁵. We systematically analysed the
37 development of anti-spike glycoprotein IgG antibody after first and second dose of COVISHIELD vaccination.
38 Startlingly, 20% of them did not develop detectable anti-spike IgG after 21 days of the first vaccination. We also
39 found that, for previously seropositive HCWs, the first dose acted as a booster dose and the detectable IgG titer
40 was significantly elevated than previous antibody level. In contrary, seronegative individuals also developed
41 detectable IgG after the first dose. Although, there was a reduction in IgG titer in pre-vaccinated follow up
42 measurements, it showed a significant increase after first dose of vaccination. A comparable median IgG (8.26
43 S/Co ratio, MAD=1.38) were observed among the RT-PCR tested positive and the previously seronegative first
44 dose vaccinated HCWs (7.35 S/Co ratio, MAD=3.06) suggested effectiveness of first dose vaccination for
45 antibody production. After administration of the second dose, ~100% of first dose seronegative individuals
46 developed detectable IgG and the antibody titer was also significantly elevated. For the first dose seropositive
47 individuals the IgG titer after the second dose was also significantly elevated. Exposure to the SARS-CoV-2
48 among the HCWs are generally higher compared to other individuals due to their involvement in patient care,
49 especially in a COVID-19 tertiary care center. SARS-CoV-2 infections among the vaccinated HCWs was found
50 to be ~12%, while the disease severity among them was very low compared to the unvaccinated HCWs.

51 Although, in our study we did not investigate the protection of antibody after vaccination on newly emerged
52 SARS-CoV-2 variants, the recent report suggest that the vaccination with ChAdOx1 nCoV-19 is as effective
53 against the B.1.1.7 variant of SARS-CoV-2 as other lineages and results in reduction in viral load as well as
54 duration of virus shedding, which obviously decrease the transmission of disease³⁴. ChAdOx-1 nCov-19
55 vaccine showed 9-fold lower *in vitro* neutralization activity against B.1.1.7 (double mutant strain) versus a
56 canonical non-B.1.1.7 strain³⁴. This observation along with the enhanced antibody generation supports the
57 immense potential of ChAdOx-1 nCov-19 vaccine. To conclude, our study, which dealt with the anti-SARS-
58 CoV-2 antibody dynamics starting from prevalence through follow-up up to the second dose of vaccination and
59 its association on several significant factors, may help to build better preventive strategies in future. Similar

1 comprehensive study over the general population following vaccination will be necessary to monitor the trend
2 and optimal resource utilization for better management of the ongoing pandemic in a large country like India.

4 **Competing interests**

5 Authors declare no competing interest.

7 **Ethical clearance**

8 The study was approved by the Institutional Ethics Committee, Niratan Sircar Medical College & Hospital, 138
9 A. J. C. Bose Road, Kolkata 700104.

11 **Author contributions**

12 SS, SM and RC conceptualize the study. SS, SD and KB performed the recruitment of participant, sample
13 collection and experiments. SS, SD and RC performed the data analysis and wrote the manuscript.

16 **References**

- 17 1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed* 2020; **91**(1): 157-60.
- 18 2. Mas-Coma S, Jones MK, Marty AM. COVID-19 and globalization. *One Health* 2020; **9**: 100132.
- 19 3. Cowling BJ, Aiello A. Public health measures to slow community spread of COVID-19. *J Infect Dis*
20 2020.
- 21 4. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in
22 China: A systematic review and meta-analysis. *J Infect* 2020; **80**(6): 656-65.
- 23 5. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical Characteristics of Patients Who Died of Coronavirus
24 Disease 2019 in China. *JAMA Netw Open* 2020; **3**(4): e205619.
- 25 6. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel
26 coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *J Infect* 2020; **80**(4):
27 388-93.
- 28 7. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J*
29 *Med* 2020; **382**(18): 1708-20.
- 30 8. Ng K, Poon BH, Kiat Puar TH, et al. COVID-19 and the Risk to Health Care Workers: A Case Report.
31 *Ann Intern Med* 2020; **172**(11): 766-7.
- 32 9. Sim MR. The COVID-19 pandemic: major risks to healthcare and other workers on the front line.
33 *Occup Environ Med* 2020; **77**(5): 281-2.
- 34 10. Karlsson U, Fraenkel CJ. Covid-19: risks to healthcare workers and their families. *BMJ* 2020; **371**:
35 m3944.
- 36 11. Misra A. Doctors and healthcare workers at frontline of COVID 19 epidemic: Admiration, a pat on the
37 back, and need for extreme caution. *Diabetes Metab Syndr* 2020; **14**(3): 255-6.
- 38 12. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine
39 antigens. *N Engl J Med* 2007; **357**(19): 1903-15.
- 40 13. Fafi-Kremer S, Bruel T, Madec Y, et al. Serologic responses to SARS-CoV-2 infection among hospital
41 staff with mild disease in eastern France. *EBioMedicine* 2020; **59**: 102915.
- 42 14. WHO. Draft landscape of COVID-19 candidates. Geneva: World Health Organization; 2021. 2021.
- 43 15. India PIBGo. PM to launch Pan India Rollout of COVID-19 Vaccination drive on 16 January. 2021.
- 44 16. Rajesh Ranjan AS, Mahendra K. Verma. Characterization of the Second Wave of COVID-19 in India.
45 *medRxiv 2021041721255665* 2021.
- 46 17. (2020) WHO. Risk assessment and management of exposure of health care workers in the context of
47 COVID-19: interim guidance, 19 March 2020. 2020.
- 48 18. Diagnostics OC. Instructions for Use—CoV2G. Pub. No. GEM1292_US_EN.
- 49 19. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-
50 mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* 2020; **38**(9): 1073-8.
- 51 20. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine
52 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*
53 2020; **396**(10249): 467-78.
- 54 21. Chan BKC. Data Analysis Using R Programming. *Adv Exp Med Biol* 2018; **1082**: 47-122.
- 55 22. ICMR. Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2
56 infection (in supersession of previous advisory dated 23rd March, 2020).
- 57 23. Steensels D, Oris E, Coninx L, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in
58 a Tertiary Center in Belgium. *JAMA* 2020; **324**(2): 195-7.

- 1 24. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection
2 in Health Care Workers. *N Engl J Med* 2021; **384**(6): 533-40.
- 3 25. Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-
4 CoV-2 among health care workers in a large Spanish reference hospital. *Nat Commun* 2020; **11**(1): 3500.
- 5 26. Rudberg AS, Havervall S, Manberg A, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in
6 healthcare workers in Sweden. *Nat Commun* 2020; **11**(1): 5064.
- 7 27. Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 Seropositive Antibody Test
8 With Risk of Future Infection. *JAMA Intern Med* 2021; **181**(5): 672-9.
- 9 28. Goenka M, Afzalpurkar S, Goenka U, et al. Seroprevalence of COVID-19 Amongst Health Care
10 Workers in a Tertiary Care Hospital of a Metropolitan City from India. *J Assoc Physicians India* 2020; **68**(11):
11 14-9.
- 12 29. Mansour M, Leven E, Muellers K, Stone K, Mendu DR, Wajnberg A. Prevalence of SARS-CoV-2
13 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City. *J Gen Intern Med*
14 2020; **35**(8): 2485-6.
- 15 30. Murhekar MV, Bhatnagar T, Thangaraj JWV, et al. SARS-CoV-2 seroprevalence among the general
16 population and healthcare workers in India, December 2020-January 2021. *Int J Infect Dis* 2021; **108**: 145-55.
- 17 31. Murhekar MV, Bhatnagar T, Selvaraju S, et al. SARS-CoV-2 antibody seroprevalence in India,
18 August-September, 2020: findings from the second nationwide household serosurvey. *Lancet Glob Health* 2021;
19 **9**(3): e257-e66.
- 20 32. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist
21 for months. *Science* 2020; **370**(6521): 1227-30.
- 22 33. Self WH, Tenforde MW, Stubblefield WB, et al. Decline in SARS-CoV-2 Antibodies After Mild
23 Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August
24 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**(47): 1762-6.
- 25 34. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine
26 against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised
27 controlled trial. *Lancet* 2021; **397**(10282): 1351-62.

28

29

1 **Figure Legends**

2 **Figure 1. Seroprevalence among health care workers (A)** Seroprevalence using anti-SARS-CoV-2 IgG and
3 total antibody in four groups of HCWs. **(B)** Signal/cut off ratio of IgG and total antibody of IgG positive HCWs.
4 **(C)** Signal/cut off ratio of IgG and total antibody of IgG negative HCWs. **(D)** Seroprevalence among COVID-19
5 suggestive symptomatic and asymptomatic individuals. Around 25% more symptomatic individuals developed
6 antibody than asymptomatic individuals.

7
8 **Figure 2. (A)** Correlation between IgG and neutralizing antibody titer (S/Co ratio). The line graph shows
9 significant positive correlation between IgG and neutralizing antibody titer. **(B)** Case infection ratio among four
10 occupational risk groups and all (total) samples.

11
12 **Figure 3. IgG dynamics among seropositive HCWs with time (A)** IgG titer measured at 0-2 months, 2-4
13 months and 4-6 months post infection among RT-PCR confirmed COVID-19 cases. **(B)** Total antibody titer
14 measured at 0-2 months, 2-4 months and 4-6 months post infection among RT-PCR confirmed COVID-19
15 cases. **(C)** Pie chart representing proportion of HCWs with IgG S/Co ratio at 0-2 months, 2-4 months and 4-6
16 months post infection among RT-PCR confirmed COVID-19 cases. **(D)** IgG titer (S/Co ratio) and the same after
17 following up at two months interval.

18
19 **Figure 4. (A)** Pie chart representing proportion of IgG reactive and non-reactive HCWs after first dose of
20 vaccination. **(B-C)** IgG titer (S/Co ratio) among previously IgG **B)** seropositive HCWs after first dose of
21 vaccination and **C)** seronegative HCWs after first dose of vaccination. **(D)** IgG titer (S/Co ratio) among
22 naturally infected IgG seropositive HCWs and seronegative HCWs after first dose of vaccination. **(E-F)** IgG
23 titer at 21 days post first and second dose of vaccines among **E)** seronegative and **F)** seropositive HCWs after
24 first dose vaccination. **(G)** The longitudinal data of IgG titers (S/Co ratio) from first measured to second dose of
25 vaccination. **(H)** IgG titer (S/Co ratio) among the vaccinated HCWs with or without SARS-CoV-2 infection
26 within 3 months post vaccination.

27

1

Table 1: Demographic details of study participants

		ALL (n=313)	Group A (n=104)	Group B (n=81)	Group C (n=66)	Group D (n=62)
Sex	Male	168	83	1	35	49
	Female	145	21	80	31	13
Age	Median	36	38	40	26	41
	Mean (SD)	37.83 (12.31)	39.71 (12.39)	40.6 (12.74)	26.89 (3.68)	42.72 (11)
Working in COVID Unit		161	35	45	43	38
No underlying illness		244	81	56	61	46
HCQ Prophylaxis taken		86	12	21	19	34
Symptomatic		119	48	27	25	19

2

3

4

Table 2: Association of COVID-19 symptoms with SARS-CoV-2 infection

Total Sample		
Factors	Odds Ratio (95% CI)	P value
Sex	1.18 (0.74-1.88)	0.4798
COVID-19 Suggestive Symptoms	3.49 (2.14-5.70)	3.05E-07
Fever and Headache	3.39 (2.05-5.62)	1.18E-06
GI upset	2.88 (1.06-7.81)	0.03035
Cough and Sore throat	2.24 (1.26-3.97)	0.005051
HCQ Prophylaxis	0.77 (0.44-1.30)	0.3285

5

Figure 1








Figure 2

A)



B)






Figure 3


A)



B)



C)



D)




Figure 4

